

Multi Drug Resistant Antibiotics Market, 2012 to 2023

<https://marketpublishers.com/r/M5B2096EB0DEN.html>

Date: December 2017

Pages: 218

Price: US\$ 4,400.00 (Single User License)

ID: M5B2096EB0DEN

Abstracts

Global Multi-Drug Resistant Antibiotics Market

Market Outline: Multi-Drug Resistant Antibiotics Market

Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria.

Market Dynamics: Multi-Drug Resistant Antibiotics Market

Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization's initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the multi drug resistant antibiotics market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period.

Market Scope: Multi Drug Resistant Antibiotics Market

Global multi drug resistant antibiotics market is segmented based on type of bacteria, disease and distribution channel

Based on type of bacteria, it is segmented into

- Multi Drug Resistant Enterococci
- Multi Drug Resistant Staphylococci
- Gram Negatives
- Others

Based on disease, it is segmented into

- Drug Resistant Tuberculosis
- Others

Based on distribution channel, it is segmented into

- Hospital Pharmacies
- Retail Pharmacies
- Others

Market Summary: Multi Drug Resistant Antibiotics Market

Emergence of antimicrobial resistance is a major concern, particularly in low and middle-income countries. Multi drug resistance antibiotics market is at growing stage owing to the availability of limited drug resistant antibiotics and there is a huge development need for the novel drugs. The market has many players who are actively participating in the development of the new treatment for multi drug resistant bacterial diseases. For instance, in February 2017, Discuva Ltd., drug discovery company expanded its collaboration with F. Hoffmann-La Roche AG in development of new antibiotic for the life-threatening infections caused by multi drug resistant bacteria and collaboration was originally initiated in February 2014. Furthermore, government and non-government organizations are funding in R&D and spreading awareness related to multi drug resistant antibiotics. Development of novel antibiotics such as plazomicin (in Phase III CL) by Achaogen, Cadazolid (in Phase III CL) by Acetlion Pharmaceuticals and many other companies and their expected commercialization in coming years may drive the market growth furthermore.

Region Analysis: Multi Drug Resistant Antibiotics Market

Geographically, multi drug resistant antibiotics market has been segmented into Latin

America, Europe, Asia- Pacific, North America, and the Middle East & Africa. North America multi drug resistant market is expected to grow at significant rates owing to the factors such as growing awareness and increase in R&D activities in developing the novel drugs for multi drug resistant infections and well-established healthcare infrastructure. Europe market is driven by the increase in prevalence of the multi drug resistant infections and developed healthcare infrastructure. Asia Pacific multi drug resistant market is expected to grow at notable rates owing to low cost of R&D and expansion of the multinational companies into the developing countries such as India.

Market Participants: Multi Drug Resistant Antibiotics Market

Some of the players in Multi-Drug Resistant Antibiotics Market are F. Hoffmann-La Roche AG (Switzerland), Achaogen Inc. (U.S.), Acetlion Pharmaceuticals (Switzerland), Sanofi S.A (France), Johnson & Johnson Services Inc. (U.S.), Pfizer Inc. (U.S.), Otsuka Pharmaceutical (Japan), and Eli Lilly and Company (U.S.) to name a few.

Notable Market Developments: Multi Drug Resistant Antibiotics Market

In August 2017, U.S. FDA approved The Medicines Company's Vabomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria

In May 2014, U.S. FDA approved Durata Therapeutic's (acquired by Actavis) Dalvance (dalbavancin), new anti-bacterial drug for the methicillin-resistant *Staphylococcus aureus* (MRSA) infections

Key Features of the Report

The report provides granular level information about The market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about The competitor's overview, key findings and Their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry

The report tracks recent innovations, key developments and startup's details that are working in The industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET INTRODUCTION

2.1. Global Multi Drug Resistant Antibiotics Market – Taxonomy

2.2. Global Multi Drug Resistant Antibiotics Market –Definitions

2.2.1. Type of Bacteria

2.2.2. Distribution Channel

3. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Multi Drug Resistant Antibiotics Market Dynamics – Factors Impact Analysis

3.6. Global Multi Drug Resistant Antibiotics Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Multi Drug Resistant Antibiotics Market – Product Innovations

4. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET, BY TYPE OF BACTERIA, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Type of Bacteria Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

5.1.1. Multi Drug Resistant Enterococci

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

5.1.2. Multi Drug Resistant Staphylococci

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

5.1.3. Gram Negatives

5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.1.4. Others

5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.4.3. Market Opportunity Analysis

6. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Drug Resistant Tuberculosis

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Others

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

7. MARKET OPPORTUNITY ANALYSIS GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Others

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

8. GLOBAL MULTI DRUG RESISTANT ANTIBIOTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

8.6. Global Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease Type, End User, and Region, 2017 – 2023

9. NORTH AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by

Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Multi Drug Resistant Enterococci

9.1.1.2. Multi Drug Resistant Staphylococci

9.1.1.3. Gram Negatives

9.1.1.4. Others

9.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Drug Resistant Tuberculosis

9.1.2.2. Others

9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospital Pharmacies

9.1.3.2. Retail Pharmacies

9.1.3.3. Others

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Disease, End User and Country, 2017 – 2023

9.1.6. North America Multi Drug Resistant Antibiotics Market Dynamics – Trends

10. EUROPE MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Multi Drug Resistant Enterococci

10.1.1.2. Multi Drug Resistant Staphylococci

10.1.1.3. Gram Negatives

10.1.1.4. Others

10.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Drug Resistant Tuberculosis

10.1.2.2. Others

10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospital Pharmacies

10.1.3.2. Retail Pharmacies

10.1.3.3. Others

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023

10.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends

11. ASIA-PACIFIC MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Multi Drug Resistant Enterococci

11.1.1.2. Multi Drug Resistant Staphylococci

11.1.1.3. Gram Negatives

11.1.1.4. Others

11.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Drug Resistant Tuberculosis

11.1.2.2. Others

11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Hospital Pharmacies

11.1.3.2. Retail Pharmacies

11.1.3.3. Others

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023

11.1.6. Europe Multi Drug Resistant Antibiotics Market Dynamics – Trends

12. LATIN AMERICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Multi Drug Resistant Enterococci

12.1.1.2. Multi Drug Resistant Staphylococci

12.1.1.3. Gram Negatives

12.1.1.4. Others

12.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Drug Resistant Tuberculosis

12.1.2.2. Others

12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospital Pharmacies

12.1.3.2. Retail Pharmacies

12.1.3.3. Others

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023

12.1.6. Latin America Multi Drug Resistant Antibiotics Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA MULTI DRUG RESISTANT ANTIBIOTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 13.1.1. Type of Bacteria Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 13.1.1.1. Multi Drug Resistant Enterococci
 - 13.1.1.2. Multi Drug Resistant Staphylococci
 - 13.1.1.3. Gram Negatives
 - 13.1.1.4. Others
- 13.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.2.1. Drug Resistant Tuberculosis
 - 13.1.2.2. Others
- 13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 13.1.3.1. Hospital Pharmacies
 - 13.1.3.2. Retail Pharmacies
 - 13.1.3.3. Others
- 13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 13.1.4.1. Gulf Cooperation Council (GCC) Countries
 - 13.1.4.2. Israel
 - 13.1.4.3. South Africa
 - 13.1.4.4. Rest of MEA
- 13.1.5. MEA Multi Drug Resistant Antibiotics Market - Opportunity Analysis Index, By Type of Bacteria, Distribution Channel, and Country, 2017 – 2023
- 13.1.6. MEA Multi Drug Resistant Antibiotics Market Dynamics – Trends

14. COMPETITION LANDSCAPE

- 14.1. Strategic Dashboard of Top Market Players
- 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
 - 14.2.1. Achaogen, Inc (U.S.)
 - 14.2.2. Actelion Pharmaceuticals (Switzerland)
 - 14.2.3. GlaxoSmithKline Plc (U.K.)
 - 14.2.4. F. Hoffmann La Roche (Switzerland)
 - 14.2.5. Eli Lilly and Company (U.S.)
 - 14.2.6. Sanofi S.A. (France)
 - 14.2.7. Johnson & Johnson Services Inc., (U.S.)
 - 14.2.8. Pfizer Inc., (U.S.)
 - 14.2.9. Otsuka pharmaceutical (Japan)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Multi Drug Resistant Antibiotics Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/M5B2096EB0DEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M5B2096EB0DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970